Antibiotic

Antimicrobial Susceptibility Testing Market worth $4.7 billion | MarketsandMarkets

Retrieved on: 
Wednesday, March 1, 2023
Infection, Patient, Culture, Academic institution, Diagnosis, BD, Hospital, Antimicrobial, India, Investment, Growth, AST, Antibiotic, USD, Prevalence, Medical device, Pharmaceutical industry, Vaccine, Antibiotics, Retail

Based on the product type, the antimicrobial susceptibility testing market is segmented into Manual antimicrobial susceptibility testing products, Automated Laboratory Instruments, Culture and Growth Media, and Consumables.

Key Points: 
  • Based on the product type, the antimicrobial susceptibility testing market is segmented into Manual antimicrobial susceptibility testing products, Automated Laboratory Instruments, Culture and Growth Media, and Consumables.
  • North America accounted for the largest share of 35.4% of the antimicrobial susceptibility testing market in 2022.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=206359984
    Antimicrobial Susceptibility Testing Market Advantages:
    Antimicrobial susceptibility testing (AST) is a laboratory technique used to determine the susceptibility or resistance of microorganisms to antimicrobial drugs.
  • Here are some advantages of the antimicrobial susceptibility testing market:
    Accurate Diagnosis: Antimicrobial susceptibility testing provides accurate and reliable results for the diagnosis of bacterial infections.

Antimicrobial Susceptibility Testing Market worth $4.7 billion | MarketsandMarkets

Retrieved on: 
Wednesday, March 1, 2023
Infection, Patient, Culture, Academic institution, Diagnosis, BD, Hospital, Antimicrobial, India, Investment, Growth, AST, Antibiotic, USD, Prevalence, Medical device, Pharmaceutical industry, Vaccine, Antibiotics, Retail

Based on the product type, the antimicrobial susceptibility testing market is segmented into Manual antimicrobial susceptibility testing products, Automated Laboratory Instruments, Culture and Growth Media, and Consumables.

Key Points: 
  • Based on the product type, the antimicrobial susceptibility testing market is segmented into Manual antimicrobial susceptibility testing products, Automated Laboratory Instruments, Culture and Growth Media, and Consumables.
  • North America accounted for the largest share of 35.4% of the antimicrobial susceptibility testing market in 2022.
  • Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=206359984
    Antimicrobial Susceptibility Testing Market Advantages:
    Antimicrobial susceptibility testing (AST) is a laboratory technique used to determine the susceptibility or resistance of microorganisms to antimicrobial drugs.
  • Here are some advantages of the antimicrobial susceptibility testing market:
    Accurate Diagnosis: Antimicrobial susceptibility testing provides accurate and reliable results for the diagnosis of bacterial infections.

Photodisinfection Found to Eradicate Biofilms Associated With Periprosthetic Joint Infections

Retrieved on: 
Tuesday, January 17, 2023
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, PDT, Infection, ESKAPE, Photosensitizer, Teaching hospital, AIM, Staphylococcus epidermidis, Internal medicine, Staphylococcus, Staphylococcus aureus, Biofilm, Escherichia coli, University Hospital of Zürich, Disease, Mortality, Research, Antibiotic, Pharmaceutical industry, Cutibacterium

A new study published in the journal Antibiotics found that antimicrobial photodisinfection therapy (aPDT), using Ondine Biomedical Inc.’s (AIM: OBI) proprietary methylene blue-based photosensitizer in combination with a specific wavelength of light, effectively eradicated pathogen biofilms commonly associated with periprosthetic joint infections (“PJIs").

Key Points: 
  • A new study published in the journal Antibiotics found that antimicrobial photodisinfection therapy (aPDT), using Ondine Biomedical Inc.’s (AIM: OBI) proprietary methylene blue-based photosensitizer in combination with a specific wavelength of light, effectively eradicated pathogen biofilms commonly associated with periprosthetic joint infections (“PJIs").
  • The results of this study suggest that photodisinfection could be used as an effective treatment method for PJIs, replacing current, more invasive approaches and potentially shortening antibiotic treatment.
  • This would not only improve patients’ quality of life, but also reduce morbidity, mortality, antibiotic resistance, and the high healthcare costs associated with treating these infections.
  • The in vitro study, conducted by a research team from University Hospital Zurich, found that photodisinfection achieved 100% kill of the key pathogens in biofilms associated with PJIs.

F2G Announces FDA Filing Acceptance of New Drug Application for Olorofim for the Treatment of Invasive Fungal Infections

Retrieved on: 
Monday, December 19, 2022
Fungus, Disease, PDUFA, Scopulariopsis, Food, Mycosis, MD, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Antibiotic, File, NDA, DHODH, Patient, Mortality, Aspergillosis, Prescription Drug User Fee Act, FDA, Breakthrough therapy, Coccidioides, New Drug Application, Pharmaceutical industry, F2G

F2G has requested approval of the NDA under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) for a limited, well-defined population with invasive fungal infections and limited or no treatment options.

Key Points: 
  • F2G has requested approval of the NDA under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) for a limited, well-defined population with invasive fungal infections and limited or no treatment options.
  • Under the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of June 17, 2023.
  • “Invasive fungal infections cause substantial morbidity and mortality, particularly among immunosuppressed patients, and can prove to be lethal in also healthy individuals when they get into deeper tissues.
  • If approved, olorofim will be the first of a new class of antifungal drugs.”
    Olorofim is the only antifungal medication to be awarded Breakthrough Therapy Designation by the FDA.

Global Vaginitis Therapeutics Market to Reach $5.2 Billion by 2027

Retrieved on: 
Tuesday, November 1, 2022
Growth, News America Marketing, Antibiotic, Future, Vaginitis, COVID-19, Current, CAGR, Therapy, Product, National Defense Authorization Act for Fiscal Year 2012, OTC, Pharmaceutical industry, Pet, Birth control, Whaling, Cereal, Security (finance), Iron ore

View original content:https://www.prnewswire.com/news-releases/global-vaginitis-therapeutics-m...

Key Points: 
  • In the changed post COVID-19 business landscape, the global market for Vaginitis Therapeutics estimated at US$3 Billion in the year 2020, is projected to reach a revised size of US$5.2 Billion by 2027, growing at a CAGR of 8% over the analysis period 2020-2027.
  • The U.S. Market is Estimated at $823.7 Million, While China is Forecast to Grow at 12.2% CAGR
    The Vaginitis Therapeutics market in the U.S. is estimated at US$823.7 Million in the year 2020.
  • China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2027 trailing a CAGR of 12.2% over the analysis period 2020 to 2027.
  • Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$709.3 Million by the year 2027.

Global OTC Topical Drugs Market Report 2022: Increasing Number of Skin Diseases and the Prevalence of Musculoskeletal Pain Driving Sector - ResearchAndMarkets.com

Retrieved on: 
Monday, October 24, 2022
Health, Pharmaceutical, Cream, Online, Skin, Prevalence, Growth, Country, Population, Drug class, Analgesic, Distribution, Pfizer, Antibiotic, Piramal, Novartis, Global, APAC, Research, Astringent, Crowding, Pain management, Investment, Skin condition, Sanofi, MEA, Mometasone, Industry, Personal care, Teva Pharmaceuticals, Market share, Lists of diseases, OTC, Lists of countries and territories, Hospital, Life expectancy, Formulation, COVID-19, USD, Consumer, Eye, Pharmaceutical industry, Medical device, Health insurance, Healthcare, Petroleum jelly, Antipruritic, Bayer, Lotion

According to a research report published in August 2022, the Global OTC Topical drugs market was valued at USD 44.6 billion in the year 2021.

Key Points: 
  • According to a research report published in August 2022, the Global OTC Topical drugs market was valued at USD 44.6 billion in the year 2021.
  • The global OTC Topical Drugs Market is driven by an increasing number of skin diseases and the prevalence of musculoskeletal pain across the globe.
  • The report analyses the OTC Topical Drugs Market By Indication (Skin Disease management, Pain Management, Eye and Ear care, Others)
    The report analyses the OTC Topical Drugs Market by End User (Personal Care, Hospitals and clinics and others).
  • The Global OTC Topical Drugs Market has been analysed By Region (Americas, Europe, Asia Pacific, and MEA).

Day Zero Diagnostics Awarded $8.2 Million in Additional CARB-X Funding To Support Ongoing Development of its Infectious Disease Rapid Diagnostic

Retrieved on: 
Thursday, October 20, 2022
Zero, Hive, LinkedIn, Education, Therapy, Infection, Machine learning, Subclinical infection, Drug resistance, Federal, Program, Massachusetts General Hospital, Administration, Association, CEO, Antibiotic, Harvard University, Boston University, News, CDC, United States Department of Health and Human Services, Biomedical Advanced Research and Development Authority, Federal Ministry of Science and Technology, MassChallenge, Twitter, Malaria, WHO, Department, BMBF, HIV/AIDS, Foundation, FDA, Risk, Development, Growth, Review, Human services, Diagnosis, American Association for Clinical Chemistry, Death, Sepsis, Culture, Federal Ministry of Education and Research (Germany), Patient, Partnership, Lancet, WGS, Priority, Vaccine, Antibiotics, Wellcome, Research

BOSTON and WASHINGTON, Oct. 20, 2022 /PRNewswire/ -- Day Zero Diagnostics Inc., an infectious disease diagnostics company utilizing genome sequencing and machine learning to combat the rise of antibiotic-resistant infections, today announced it was awarded $8.2 million in additional option stage funding from CARB-X, the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, a global non-profit partnership dedicated to accelerating early antibacterial research and development to address the rising global threat of drug-resistant bacteria. The company received an initial $6.2 million CARB-X award in May of 2020. This latest award brings the total to over $16 million.

Key Points: 
  • Day Zero Diagnostics is determined to bend the curve on antibiotic resistance growth by enabling rapid and accurate diagnosis," said Jong Lee, CEO of Day Zero Diagnostics.
  • "We are pleased to support Day Zero Diagnostics' development of its rapid infectious disease diagnostic technology," said Erin Duffy, Ph.D., Chief of Research and Development at CARB-X.
  • Option Stage funding from CARB-X will enable Day Zero to transition into product development of its diagnostic system.
  • Day Zero Diagnostics announced the news today from IDWeek in Washington, D.C.
    Research reported in this press releaseis supported by CARB-X.

American Molecular Labs selects 1health.io for its Direct-to-Consumer Test and Ordering Platform

Retrieved on: 
Tuesday, October 18, 2022
Software, Research, General Health, Data Management, Oncology, Technology, Medical Devices, Infectious Diseases, Health Technology, Science, Biotechnology, Health, Other Science, Physician, Disease, Helicobacter pylori, Efficiency, Diagnosis, Infection, AML, Laboratory, Science, Food allergy, Drug development, Hospital, Research, Gastroenterology, Partnership, Cancer, Meta-analysis, Peptic ulcer disease, Transparency (market), Company, Systematic review, Starbucks, Tan Hooi Ling, Gastrointestinal tract, Antibiotic, United, Gold, Lymphoma, Human, Medical imaging, Pharmaceutical industry, Online shopping

American Molecular Laboratories specializes in the diagnosis of infection, disease, and early detection cancer screening predominantly in the gastrointestinal tract.

Key Points: 
  • American Molecular Laboratories specializes in the diagnosis of infection, disease, and early detection cancer screening predominantly in the gastrointestinal tract.
  • We have a strong science team that is driving innovation, accuracy, and efficiency within American Molecular Labs.
  • American Molecular Laboratories offers the only test in the world, its H. pylori test, that uses a non-evasive mechanism to test gastric malignancies, including certain types of cancer and lymphomas.
  • American Molecular Laboratories (AML) is a state-of-the-art molecular diagnostic and biotech development company that was founded by Sam Zhang and an expert scientific team in molecular diagnostics.

Superbugs in Stock report shows grocery stores failing to stop antibiotic overuse in meat supply chains.

Retrieved on: 
Thursday, October 13, 2022
Food Lion, Food Animal Concerns Trust, ARAC, Menu, Disease, FACT, Animal, Public health, Stop & Shop, Humane Farm Animal Care, Infection, Antibiotic, Farm, Organization, Social change, Farmer, Private sector, Research, Twitter, Bacteria, Instagram, World Animal Protection, Food safety, Health, Safety, Center for Food Safety and Applied Nutrition, Walmart, George Washington University, Leadership, Food, Environment, Ahold Delhaize, George Washington University School of Engineering and Applied Science, Death, Commodification, Center, COVID-19, Poultry, Solution, Meat, Milken Institute School of Public Health, Grocery store, Agriculture, Online shopping, Pharmaceutical industry, Giant

"As rampant overuse of antibiotics leads to the spread of resistant superbugs, more people are getting sick, becoming hospitalized, and dying from common infections -- up to 160,000 U.S. deaths each year," said Steven Roach, FACT's safe & healthy food program director and a lead author of the report. "As big meat buyers, grocers need to do more to make sure the meat they sell is not contributing to this serious health threat."

Key Points: 
  • "It is evident that the grocery sector has taken little action to address misuse of antibiotics in their meat and poultry supplies.
  • These bacteria can then end up in our food system via the meat reaching grocery shelves.
  • Superbugs in Stock ranks the grocers by how well they minimize routine antibiotic usage in otherwise healthy animals.
  • "Now, consumers know where each grocery store stands in its efforts, or lack thereof, to reduce antibiotic use in the meat supply chain.

Global Bioprocess Analyzers Market Report to 2027 - Featuring Agilent Technologies, Danaher, Emerson Electric and Merck Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 27, 2022
Science, Other Science, Research, Observation, Porter's five forces analysis, COVID-19, Competitive analysis, A-DNA, Risk, Contract, LLC, Geography, Growth, Ansoff Matrix, Industry, Market development, USD, Investment, Emotion, Agilent Technologies, SWOT, Consumables, CAGR, Medical device, Marketing, Retail, Risk management, Antibiotic

The Global Bioprocess Analyzers Market is estimated to be worth USD 498.14 million in 2022, and is expected to reach USD 837.13 million by 2027, growing at a CAGR of 10.94%.

Key Points: 
  • The Global Bioprocess Analyzers Market is estimated to be worth USD 498.14 million in 2022, and is expected to reach USD 837.13 million by 2027, growing at a CAGR of 10.94%.
  • The report presents a detailed Ansoff matrix analysis for the Global Bioprocess Analyzers Market.
  • The Global Bioprocess Analyzers Market is analyzed using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global Bioprocess Analyzers Market.